Physician profile
William B Moore
NPI 1457794570
$12,907.83
in general payments reported to CMS, 2019-2025
39 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,323 · 2020: $1,841 · 2021: $849 · 2022: $1,779 · 2023: $1,769 · 2024: $2,195 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,919 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151 · Education: $48.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,918.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.62 |
| Education | $48.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,821.40 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Lilly USA, LLC | $1,608.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,352.35 | 2021-2025 | |
| Abbott Laboratories | $1,060.96 | 2019-2025 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $872.95 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Dexcom, INC. | $795.31 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $628.83 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $591.30 | 2019-2022 | |
| Amgen INC. | $419.39 | 2019-2025 | Evenity, Tepezza, Prolia |
| Medtronic, INC. | $408.15 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $370.25 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $334.33 | 2019-2025 | |
| Medtronic Minimed, INC. | $274.16 | 2019-2020 | |
| Ibsa Pharma INC. | $266.47 | 2019-2025 | Tirosint, Licart, Tirosint |
| Abbvie INC. | $264.37 | 2020-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $241.31 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $240.74 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insulet Corporation | $189.12 | 2019-2025 | Omnipod |
| Actelion Pharmaceuticals US, INC. | $149.89 | 2024 | Uptravi |
| Horizon Therapeutics Plc | $136.55 | 2019-2020 | |
| Sequel Med Tech, LLC | $117.64 | 2025 | Twiist |
| Kowa Pharmaceuticals America, INC. | $116.21 | 2019 | |
| Radius Health, INC. | $89.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $77.91 | 2023-2025 | |
| Amarin Pharma, INC. | $66.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $52.41 | 2023-2024 | Shingrix, Arexvy |
| Neurocrine Biosciences, INC. | $48.08 | 2025 | |
| Merck Sharp & Dohme LLC | $48.01 | 2019-2021 | |
| Pfizer INC. | $45.47 | 2019-2024 | |
| Averitas Pharma INC. | $38.55 | 2024 | Qutenza |
| Endogastric Solutions, INC | $30.00 | 2024 | Esophyx |
| Janssen Pharmaceuticals, INC | $28.14 | 2019-2020 | |
| Shire North American Group INC | $26.02 | 2019 | |
| Kyowa Kirin, INC. | $20.95 | 2025 | |
| Ironshore Pharmaceuticals INC. | $18.13 | 2020 | |
| Tolmar, INC. | $16.70 | 2023 | |
| Daiichi Sankyo INC. | $16.04 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.